 LA JOLLA, Calif., Feb. 08, 2021 GLOBE NEWSWIRE -- Artelo Biosciences, Inc. NASDAQ: ARTL, a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing. Existing investors agreed to exercise warrants for net proceeds of approximately 3 million. 